Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of YK012 in relapsed or refractory B-cell non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• YK012

Snippet

Sponsor: Excyte Biopharma Ltd | Conditions: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING